{"nctId":"NCT00495157","briefTitle":"Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)","startDateStruct":{"date":"2007-06"},"conditions":["Asthma"],"count":342,"armGroups":[{"label":"Symptom-based adjustment","type":"EXPERIMENTAL","interventionNames":["Behavioral: Symptom-based adjustment"]},{"label":"Biomarker-based adjustment","type":"EXPERIMENTAL","interventionNames":["Behavioral: Biomarker-based adjustment"]},{"label":"Guideline-based adjustment","type":"EXPERIMENTAL","interventionNames":["Behavioral: Guideline-based adjustment"]}],"interventions":[{"name":"Symptom-based adjustment","otherNames":[]},{"name":"Biomarker-based adjustment","otherNames":[]},{"name":"Guideline-based adjustment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for BASALT and TALC Studies:\n\n* Clinical history consistent with asthma\n* Forced expiratory volume in one second (FEV1) greater than 40% of predicted value\n* Asthma confirmed by one of the following two criteria:\n\n  1. Beta-agonist reversibility to 4 puffs albuterol of at least 12% OR\n  2. Methacholine provocative concentration at 20% (PC20) FEV1 of 8 milligrams per millimeter (mg/mL) or less when not on an inhaled corticosteroid, or 16 mg/mL or less when on an inhaled corticosteroid\n* Need for daily controller therapy (i.e., inhaled corticosteroids, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following criteria:\n\n  1. Received prescription for or used asthma controller within the 12 months prior to study entry OR\n  2. Experienced symptoms for more than twice a week and not on asthma controller\n* If on inhaled steroids (any drug at any dose not exceeding the equivalent of 1000 micrograms (mcg) of fluticasone daily), participant must have been on a stable dose for at least 2 weeks prior to study entry\n* Non-smoker (i.e., total lifetime smoking history less than 10 pack-years; no smoking for at least 1 year prior to study entry)\n* Willing to use an effective form of birth control throughout the study\n\nInclusion Criteria for BASALT Study:\n\n* Ability to measure peak expiratory flow (PEF) each morning using the electronic peak flow meter (EPFM) device and to accurately transcribe the PEF measurements onto the diary cards at least 75% of the time during the last 2 weeks of the adherence testing period\n* 75% compliance with recording peak flow measurements and symptoms in a symptom diary during the last 2 weeks of the adherence testing period\n* Ability to take Inhalers A, B, and C at least 75% of scheduled doses; 75% compliance per inhaler is required\n* No treatment failure (includes significant asthma exacerbation) within the last 4 weeks\n\nExclusion Criteria for BASALT and TALC Studies:\n\n* Lung disease other than asthma, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis\n* Established or suspected diagnosis of vocal cord dysfunction\n* Significant medical illness other than asthma\n* History of respiratory tract infection within the 4 weeks prior to study entry\n* History of a significant exacerbation of asthma within the 4 weeks prior to study entry\n* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the 5 years prior to study entry\n* Hyposensitization therapy other than an established maintenance regimen\n* Inability to coordinate use of the delivery devices used in the study, based on the opinion of the investigator or clinical coordinator\n* Pregnant\n\nExclusion Criteria for BASALT Study:\n\n* Inability to coordinate use of the medication delivery devices used in the study, based on the opinion of the investigator or clinical coordinator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Treatment Failure (Measured in Days)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196.9","spread":"4.0"},{"groupId":"OG001","value":"225.2","spread":"5.6"},{"groupId":"OG002","value":"182.3","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Number of Episodes of Treatment Failure","description":null,"classes":[]},{"type":"SECONDARY","title":"Time to First Asthma Exacerbation","description":null,"classes":[]},{"type":"SECONDARY","title":"Number of Asthma Exacerbations","description":null,"classes":[]},{"type":"SECONDARY","title":"Tests of Airway Caliber and Responsiveness (Forced Expiratory Volume in One Second (FEV1) Pre- and Post-bronchodilator Inhalation), Methacholine Provocative Concentration at 20% (PC20)","description":null,"classes":[]},{"type":"SECONDARY","title":"Tests of Airway Inflammation (Exhaled Breath Condensate (EBC), Fractional Exhaled Nitric Oxide (FeNO), Sputum Eosinophils)","description":null,"classes":[]},{"type":"SECONDARY","title":"Quality-of-life (AQLQ), Asthma Control Questionnaire (ACQ), and Number of Visit Days That ACQ is Less Than 1.25","description":null,"classes":[]},{"type":"SECONDARY","title":"Total Amount of Oral Prednisone Required and Total Amount of Inhaled Steroids","description":null,"classes":[]},{"type":"SECONDARY","title":"Adverse Events","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":113},"commonTop":["urgent care for asthma"]}}}